RLMD Relmada Therapeutics
- 3.340
- -0.150-4.30%
Relmada Therapeutics News
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2024 Earnings Call Transcript
Earnings Call Summary | Relmada Therapeutics(RLMD.US) Q1 2024 Earnings Conference
The following is a summary of the Relmada Therapeutics, Inc. (RLMD) Q1 2024 Earnings Call Transcript:Financial Performance:Relmada Therapeutics reported a decrease in total research and development ex
Buy Rating for Relmada Therapeutics Supported by Strong Clinical Pipeline and Financial Stability
Relmada Therapeutics Inc (RLMD) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
Relmada Therapeutics Q1 2024 GAAP EPS $(0.72) Beats $(0.84) Estimate
Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(0.84) by 14.29 percent. This is a 17.24 percent increase over losses of
Relmada Therapeutics | 10-Q: Quarterly report
Press Release: Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results PR Newswire CORAL GABLES, Fla., May 8, 2024 CORAL GABLES, Fla., May 8, 2024 /PRNewswire/ -- Relmada T
Major Depressive Disorder Pipeline Insights Report, 2024 Featuring 75+ Companies and Pipeline Drugs, Including SAGE-217 (Sage Therapeutics) and REL-1017 (Relmada Therapeutics)
Relmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...
Optimistic Outlook for Relmada Therapeutics: A Comprehensive Analysis and Buy Rating
Earnings Call Summary | Relmada Therapeutics(RLMD.US) Q4 2023 Earnings Conference
The following is a summary of the Relmada Therapeutics, Inc. (RLMD) Q4 2023 Earnings Call Transcript:Financial Performance:Information not provided.Business Progress:Information not provided.More deta
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2023 Earnings Call Transcript
Relmada Therapeutics Inc Reports Full-Year and Q4 2023 Financial Results
Relmada Therapeutics Q4 EPS $(0.84) Misses $(0.83) Estimate
Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(0.84) per share which missed the analyst consensus estimate of $(0.83) by 1.2 percent. This is a 34.38 percent increase over losses of
Recap: Relmada Therapeutics Q4 Earnings
Relmada Therapeutics (NASDAQ:RLMD) reported its Q4 earnings results on Tuesday, March 19, 2024 at 04:15 PM.Here's what investors need to know about the announcement.EarningsRelmada Therapeutics missed
Relmada Therapeutics GAAP EPS of -$0.84
Relmada Therapeutics 2023 EPS $(3.28)
Relmada Therapeutics 2023 EPS $(3.28)
Relmada Therapeutics: Provides Corporate Update and Reports 4Q and Full-Yr 2023 Fincl Results
Relmada Therapeutics: Provides Corporate Update and Reports 4Q and Full-Yr 2023 Fincl Results
Relmada Therapeutics: As of Dec 31, 2023, Had Cash, Cash Equivalents, Short-Term Investments of Approximately $96.3M, Compared to Cash, Cash Equivalents, Short-Term Investments of Approximately $148.3M at Dec 31, 2022 >RLMD
Relmada Therapeutics: As of Dec 31, 2023, Had Cash, Cash Equivalents, Short-Term Investments of Approximately $96.3M, Compared to Cash, Cash Equivalents, Short-Term Investments of Approximately $148.3
Press Release: Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results PR Newswire CORAL GABLES, Fla., March 19, 2024 CORAL GABLES, Fla., March 19, 2024 /PRN
Analysis
Price Target
No Data
